Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States

No abstract is available for this paper.

• Publication year

  2013

• Venue

  American Journal of Gastroenterology

• Publication date

  2013-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ajg.2013.160PMID 23752878PMCID PMC4105976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatocellular carcinoma in non‐alcoholic steatohepatitis: Growing evidence of an epidemic?

  2012cited by this paper
• Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta‐analysis of cohort studies

  2012cited by this paper
• Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER‐medicare database

  2011cited by this paper
• Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study.

  2011cited by this paper
• Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study

  2011cited by this paper
• Hepatitis B and C Virus Infection and Hepatocellular Carcinoma in China: A Review of Epidemiology and Control Measures

  2011cited by this paper
• The global epidemiology of hepatocellular carcinoma: present and future.

  2011cited by this paper
• Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.

  2011cited by this paper
• Autoimmune Hepatitis, Cirrhosis, and Hepatocellular Carcinoma (HCC)

  2011cited by this paper
• Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection

  2010cited by this paper
• The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

  2010cited by this paper
• Ethnicity and Health Disparities in Alcohol Research

  2010cited by this paper
• Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

  2009cited by this paper
• The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis.

  2007cited by this paper
• Differences in disease prevalence as a source of the U.S.-European health care spending gap.

  2007cited by this paper
• Diabetes and liver disease: an ominous association.

  2007cited by this paper
• Tracing hepatitis C and Delta viruses to estimate their contribution in HCC rates in Mongolia

  2007cited by this paper
• The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

  2006cited by this paper
• Hepatitis Viruses, Alcohol, and Tobacco in the Etiology of Hepatocellular Carcinoma in Italy

  2006cited by this paper
• Standard Errors for Attributable Risk for Simple and Complex Sample Designs

  2005cited by this paper
• Obesity and mortality.

  2005cited by this paper
• Tobacco smoke and involuntary smoking.

  2004cited by this paper
• Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988-1994.

  2004cited by this paper
• Primary liver cancer: worldwide incidence and trends.

  2004cited by this paper
• Alcohol and hepatocellular carcinoma.

  2004cited by this paper
• Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus

  2002cited by this paper
• Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population

  2002cited by this paper
• Attributable risks for hepatocellular carcinoma in northern Italy.

  1997cited by this paper
• Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case‐control study in Italy

  1997cited by this paper
• Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study.

  1997cited by this paper
• Estimating the population attributable risk for multiple risk factors using case-control data.

  1985cited by this paper
• Proportion of disease caused or prevented by a given exposure, trait or intervention.

  1974cited by this paper

• Clinical risk factors for hepatocellular carcinoma in Southeast Louisiana: a matched case–control study

  2025cites this paper
• Hepatic Iron Overload and Hepatocellular Carcinoma: New Insights into Pathophysiological Mechanisms and Therapeutic Approaches

  2025cites this paper
• A Comparative Study of Radiofrequency Ablation, Microwave Ablation, and Percutaneous Ethanol Injection in Treatment of Hepatocellular Carcinoma—A Single-Center Experience

  2025cites this paper
• Pan-serological antibodies and liver cancer risk: a nested case-control analysis

  2025cites this paper
• Geographic diversity of human liver cancers mirrors global social inequalities

  2025cites this paper
• Mitochondrial dysfunction in hepatocellular carcinoma: from metabolism to targeted therapies

  2025cites this paper
• Ferroptosis and the cGAS-STING pathway into precision nano-immuno-theranostics: A mechanistic paradigm for reversing drug resistance in hepatocellular carcinoma.

  2025cites this paper
• Racial and Ethnic Disparities in Outcomes in Liver Transplantation for Hepatocellular Carcinoma.

  2025cites this paper
• Human leukocyte antigen-G in hepatocellular carcinoma driven by chronic viral hepatitis or steatotic liver disease

  2025cites this paper
• Liver Cancer Etiology in Asian Subgroups and American Indian, Black, Latino, and White Populations

  2025cites this paper
• Targeted degradation of GSPT1 and NEK7 by a molecular glue prodrug for treatment of HCC

  2025cites this paper
• Public health strategies for hepatocellular carcinoma: from risk factors to prevention and control

  2025cites this paper
• Non-parenchymal cells: key targets for modulating chronic liver diseases

  2025cites this paper
• Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma.

  2025cites this paper
• Epidemiological and demographic analysis of liver cancer attributable to modifiable risk factors from 1990 to 2021

  2025influential citation
• Combined anti-SPP-1 and anti-CTLA-4 immunotherapy enhances anti-tumor efficacy in hepatocellular carcinoma via IL-6/STAT3 pathway modulation

  2025cites this paper
• Racial and ethnic differences in treatment and survival for hepatocellular carcinoma patients undergoing systemic therapy

  2025cites this paper
• Hot and Cold HCC: Uncoupling Viral Oncogenesis and Therapy

  2025cites this paper
• Different Etiological Entities of Liver Cancer Across Populations: Implications From Age-Period-Cohort Analysis on Incidence Trends

  2024cites this paper
• Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019

  2024cites this paper
• Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies.

  2024cites this paper
• Risk of Malignancy in Indeterminate Liver Nodules Among Patients with Cirrhosis: A Retrospective Cohort Study

  2024cites this paper
• Hedgehog components are overexpressed in a series of liver cancer cases

  2024cites this paper
• Assessing Physicians’ Recommendations for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Testing Among Minority Populations in Greater Philadelphia and New York City

  2024influential citation
• Prospective cohort for early detection of liver cancer (Pearl): a study protocol

  2024cites this paper
• Understanding risk factors for endometrial cancer in young women.

  2024cites this paper
• The Role of microRNAs in Hepatocellular Cancer: A Narrative Review Focused on Tumor Microenvironment and Drug Resistance

  2024cites this paper
• Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin

  2024cites this paper
• Pre‐diagnostic plasma inflammatory proteins and risk of hepatocellular carcinoma in three population‐based cohort studies from the United States and the United Kingdom

  2024cites this paper
• Genetic Alchemy unveiled: MicroRNA-mediated gene therapy as the Artisan craft in the battlefront against hepatocellular carcinoma—a comprehensive chronicle of strategies and innovations

  2024cites this paper
• A Comparison of Presentation, Treatment, and Survival After Hepatocellular Carcinoma of Viral and Non-Viral Etiology in Damietta, Egypt, 2007–2019

  2024cites this paper
• Fiber and whole grain intakes in relation to liver cancer risk: An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies

  2024cites this paper
• Disparities, Trends, and Predictions to 2040 in Gastrointestinal Cancer Incidence, Mortality in the United States

  2024cites this paper
• Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma

  2024cites this paper
• Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease

  2024cites this paper
• Progress in the Study of Risk Factors Associated with Primary Liver Cancer

  2024cites this paper
• Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma.

  2024cites this paper
• Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon

  2024influential citation
• Examining the evolving landscape of liver cancer burden in the United States from 1990 to 2019

  2024cites this paper
• Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study

  2024cites this paper
• Hepatocellular Carcinoma Etiology Drives Survival Outcomes: A Population-Based Analysis.

  2024cites this paper
• Hepatocellular Carcinoma from a Hepatologist's Perspective

  2023cites this paper
• Global burden of Liver Disease: 2023 Update.

  2023cites this paper
• Hepatocellular Carcinoma: A Cross-Sectional Analysis of Risk Factors

  2023cites this paper
• Germline Genetic Associations for Hepatobiliary Cancers

  2023cites this paper
• Dietary inflammatory and insulinemic potential, risk of hepatocellular carcinoma, and chronic liver disease mortality

  2023cites this paper
• Increased age, bilirubin, international normalized ratio, and creatinine score to triglyceride ratio are associated with alcohol-associated primary liver carcinoma: a single-centered retrospective study

  2023cites this paper
• The Growing Landscape of NAFLD-Associated Hepatocellular Carcinoma and Its Impact in Surveillance

  2023cites this paper
• Daytime napping, nighttime sleeping duration, and risk of hepatocellular carcinoma and liver disease-related mortality

  2023cites this paper
• Proportion of liver cancer cases and deaths attributable to potentially modifiable risk factors in China.

  2023cites this paper
• Population-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancers

  2023cites this paper
• Prognostic biomarkers in and selection of surgical patients with hepatocellular carcinoma

  2023cites this paper
• Global patterns of cancer transitions: A modelling study

  2023cites this paper
• Ethnic disparities in the epidemiology, treatment, and outcome of patients with hepatocellular carcinoma in the United States

  2023cites this paper
• Hispanic Individuals are Underrepresented in Phase III Clinical Trials for Advanced Liver Cancer in the United States

  2023cites this paper
• Should we undertake surveillance for HCC in patients with MAFLD?

  2023cites this paper
• Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives.

  2023cites this paper
• Metabolism-related signatures is correlated with poor prognosis and immune infiltration in hepatocellular carcinoma via multi-omics analysis and basic experiments

  2023cites this paper
• Time-trends in liver cancer incidence and mortality rates in the U.S. from 1975 to 2017: a study based on the Surveillance, Epidemiology, and End Results database

  2023cites this paper
• Positive status of Hepatis B Virus seroprevalence in local people and immigrants

  2023cites this paper
• Population‐attributable risk of modifiable lifestyle factors to hepatocellular carcinoma: The multi‐ethnic cohort

  2023cites this paper
• Incidence of Etiology-specific Hepatocellular Carcinoma: diverging trends and significant heterogeneity by race and ethnicity.

  2023cites this paper
• HepaClear, a blood-based panel combining novel methylated CpG sites and protein markers, for the detection of early-stage hepatocellular carcinoma

  2023cites this paper
• Cancer mortality rates by racial and ethnic groups in the United States, 2018-2020

  2023cites this paper
• The Impact of interferon lambda 3 Polymorphism on Hepato-Cellular Carcinoma Progression in Hepatitis C Virus Patients: Treatment-Naïve and Experienced

  2023cites this paper
• Comparison of patients with hepatitis B virus-associated hepatocellular carcinoma: Data from two hospitals from Turkey and China

  2023cites this paper
• Trends in hepatocellular carcinoma stage by racial/ethnic group in the United States, 1992–2019

  2023cites this paper
• Glypican-3 (GPC-3) for early diagnosis and target therapy

  2023cites this paper
• Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis

  2022cites this paper
• Time trends and geographic distribution of hepatocellular carcinoma in Brazil: An ecological study

  2022cites this paper
• Alcohol Use and Use Disorder and Cancer Risk: Perspective on Causal Inference

  2022cites this paper
• Risk factors of liver malignancies in workers chronically exposed to ionizing radiation

  2022cites this paper
• LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma

  2022cites this paper
• Body Mass Index Trajectories, Weight Gain, and Risks of Liver and Biliary Tract Cancers

  2022cites this paper
• Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases

  2022cites this paper
• Fat and exposure to 4-nitroquinoline-1-oxide causes histologic and inflammatory changes in murine livers

  2022cites this paper
• Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges

  2022influential citation
• Frequency distribution and ten-year survival rate of patients with different malignant liver lesions in Iran ‎

  2022cites this paper
• Prediction of hepatocellular carcinoma risk in patients with type-2 diabetes using supervised machine learning classification model

  2022influential citation
• When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD

  2022cites this paper
• Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis

  2022cites this paper
• Health disparities in chronic liver disease

  2022cites this paper
• Hepatocellular Carcinoma-Related Mortality in the USA, 1999–2018

  2022cites this paper
• II Consenso Mexicano de Carcinoma Hepatocelular. Parte I: Epidemiología y diagnóstico

  2022cites this paper
• CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity

  2022cites this paper
• Anti-Cancer Activity of Buthus occitanus Venom on Hepatocellular Carcinoma in 3D Cell Culture

  2022cites this paper
• Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992–2018

  2022cites this paper
• Heparanase Inhibition Prevents Liver Steatosis in E0 Mice

  2022cites this paper
• Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.

  2022cites this paper
• Declining disease burden of HCC in the United States, 1992–2017: A population‐based analysis

  2022cites this paper
• Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies

  2022cites this paper
• [Case of multiple systemic (extrahepatic) manifestations of chronic HCV infection (analysis of the literature and own observations). Case report].

  2022cites this paper
• Elderly Patients with Hepatocellular Carcinoma Benefit from Liver Transplantation as Much as Younger Ones

  2022cites this paper
• Risk factors and pathogenic mechanism–associated hepatocellular carcinoma

  2022cites this paper
• Reducing Liver Cancer Risk through Dietary Change: Positive Results from a Community-Based Educational Initiative in Three Racial/Ethnic Groups

  2022influential citation
• FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma

  2022cites this paper
• Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease

  2022influential citation
• The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis.

  2022cites this paper
• Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet

  2022cites this paper
• Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan

  2021cites this paper